Media coverage
1
Media coverage
Title WindMIL Therapeutics Announces Dosing of First Patient in a Phase 2a Clinical Trial of Marrow-Infiltrating Lymphocytes (MILs™) for Treatment of Patients with Non-Small Cell Lung Cancer Media name/outlet Global English (Middle East and North Africa Financial Network) Country/Territory Jordan Date 12/12/19 Persons Martin Edelman